Thirty-day mortality rates after immunotherapy initiation.

Sütcüoğlu O., İlhan A., Tacar S. Y., Güven D. C., Uçar G., Karadurmuş N., ...Daha Fazla

Immunotherapy, cilt.13, ss.1419-1426, 2021 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 13
  • Basım Tarihi: 2021
  • Doi Numarası: 10.2217/imt-2021-0082
  • Dergi Adı: Immunotherapy
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, Chemical Abstracts Core, EMBASE, MEDLINE
  • Sayfa Sayıları: ss.1419-1426
  • Anahtar Kelimeler: antiaggregant drugs, atezolizumab, cancer, fatal side effects, hyperprogression, immune side effect, immunotherapy, nivolumab, palliative oncology, thromboembolism, CHECKPOINT INHIBITORS, CANCER-PATIENTS, LUNG-CANCER, REAL-WORLD, IPILIMUMAB, PEMBROLIZUMAB, CHEMOTHERAPY, NIVOLUMAB, TRIAL
  • Gazi Üniversitesi Adresli: Evet

Özet

Background: The aim of this study was to determine the cause of death in patients who died within 30 days after the first dose of immunotherapy. Methods: The data of 1432 patients treated with immunotherapy in six tertiary referral hospitals were retrospectively analyzed. Results: It was determined that 34 (2%) of the patients died within 30 days after the first dose of immunotherapy. Death occurred in all patients who received palliative therapy, and most patients (88%) received immunotherapy as second- or subsequent-line of therapy. The most common cause of death was disease progression and thromboembolic events. Conclusion: Preliminary results of the current study might give some clues to define the patient population in whom the fatal side effects of immunotherapy might be encountered.